Lantern Pharma Inc. announced that Leslie W. Kreis, Jr., the Managing Principal at Steelhead Capital Management, LLC, managing partner and co-founder of Bios Equity Partners, LP and Bios Equity Partners II, LP, and a member of Lantern Pharma's Board of Directors since 2019, has advised Lantern's Board of his determination not to stand for reelection as a Director at Lantern's Annual Meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.07 USD | -3.65% | -3.19% | +41.82% |
29/05 | Transcript : Lantern Pharma Inc. - Special Call | |
24/05 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.82% | 67.78M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director